Back

Antiplatelets and hemorrhagic MI outcome in reperfused STEMI

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Chronic coronary syndromes: antiplatelets Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Keyur Vora

Indiana University School of Medicine, Indianapolis (United States of America)

5 More presentations in this session

Presentation thumbnail
Indobufen-based dual antiplatelet therapy in patients with multivessel coronary disease undergoing drug-eluting stent implantation: insight from the OPTION trial
Doctor L. Xu (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Dual antiplatelet therapy de-escalation followed by aspirin or P2Y12 inhibitor monotherapy after PCI for acute coronary syndrome: a systematic review and meta-analysis
Doctor C. Laudani (Catania, IT)
Abstract Slides Video
Presentation thumbnail
Ticagrelor vs. clopidogrel in elderly patients following acute myocardial infarction: a multicenter international analysis
Doctor R. Ibrahim (Phoenix, US)
Abstract Slides Video
Presentation thumbnail
The effect of ticagrelor on patients with acute myocardial infarction and malnutrition
Professor K. Chen (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Duration of dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention (PCI) for bifurcation lesions: insights from the ULTRA-BIFURCAT registry
Doctor M. Nebiolo (Turin, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic coronary syndromes: antiplatelets

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
In-hospital mortality in hemorrhagic myocardial infarction
thumbnail
Congress Presentation
Upper gastrointestinal bleeding events after myocardial infarction: long-term insights from nationwide Swedish registries
thumbnail
Congress Presentation
Antiplatelet can improve the short-term prognosis of type 2 myocardial infarction caused by acute respiratory failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources